Eli Lilly and Company (LLY)vsExagen Inc (XGN)
LLY
Eli Lilly and Company
$1,210.32
-0.87%
HEALTHCARE · Cap: $1.02T
XGN
Exagen Inc
$4.35
-2.25%
HEALTHCARE · Cap: $106.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 105553% more annual revenue ($72.25B vs $68.38M). LLY leads profitability with a 35.0% profit margin vs -29.5%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
XGN
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+49.9%
Fair Value
$6.59
Current Price
$4.35
$2.24 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 34.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : XGN
Revenue growth of 11.7% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Bear Case : XGN
The primary concerns for XGN are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.76 is elevated, increasing financial risk.
Key Dynamics to Monitor
LLY profiles as a growth stock while XGN is a turnaround play — different risk/reward profiles.
XGN carries more volatility with a beta of 2.02 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 29/100), backed by strong 35.0% margins and 55.5% revenue growth. XGN offers better value entry with a 49.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Exagen Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name in the United States. The company is headquartered in Vista, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?